Literature DB >> 21455198

Familial thyroid cancer: a review.

Vânia Nosé1.   

Abstract

Thyroid carcinomas can be sporadic or familial. Familial syndromes are classified into familial medullary thyroid carcinoma (FMTC), derived from calcitonin-producing C cells, and familial non-medullary thyroid carcinoma, derived from follicular cells. The familial form of medullary thyroid carcinoma (MTC) is usually a component of multiple endocrine neoplasia (MEN) IIA or IIB, or presents as pure FMTC syndrome. The histopathological features of tumors in patients with MEN syndromes are similar to those of sporadic tumors, with the exception of bilaterality and multiplicity of tumors. The genetic events in the familial C-cell-derived tumors are well known, and genotype-phenotype correlations well established. In contrast, the case for a familial predisposition of non-medullary thyroid carcinoma is only now beginning to emerge. Although, the majority of papillary and follicular thyroid carcinomas are sporadic, the familial forms are rare and can be divided into two groups. The first includes familial syndromes characterized by a predominance of non-thyroidal tumors, such as familial adenomatous polyposis and PTEN-hamartoma tumor syndrome, within others. The second group includes familial syndromes characterized by predominance of papillary thyroid carcinoma (PTC), such as pure familial PTC (fPTC), fPTC associated with papillary renal cell carcinoma, and fPTC with multinodular goiter. Some characteristic morphologic findings should alert the pathologist of a possible familial cancer syndrome, which may lead to further molecular genetics evaluation.

Entities:  

Mesh:

Year:  2011        PMID: 21455198     DOI: 10.1038/modpathol.2010.147

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  44 in total

1.  A Papillary Thyroid Tumor Detected by (18)F-FDG-PET/CT in a Pediatric Patient with Cowden Syndrome.

Authors:  Giorgio Treglia; Carmelo Caldarella; Paola Castaldi; Barbara Muoio; Francesco Bertagna; Luca Giovanella
Journal:  Nucl Med Mol Imaging       Date:  2012-11-23

2.  Pancreatic adenocarcinoma with a germline PTEN p.Arg234Gln mutation.

Authors:  Sunao Uemura; Hiroyuki Matsubayashi; Yoshimi Kiyozumi; Katsuhiko Uesaka; Yusuke Yamamoto; Keiko Sasaki; Masato Abe; Kenichi Urakami; Masatoshi Kusuhara; Ken Yamaguchi
Journal:  Fam Cancer       Date:  2018-04       Impact factor: 2.375

Review 3.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

4.  The clinical management in familial adenomatous polyposis deserves continuous monitoring for thyroid carcinoma.

Authors:  Stefano Crippa; Piercarlo Saletti; Jessica Barizzi; Luca Mazzucchelli
Journal:  BMJ Case Rep       Date:  2012-11-15

Review 5.  Genetic predisposition for nonmedullary thyroid cancer.

Authors:  Rebecca Nagy; Matthew D Ringel
Journal:  Horm Cancer       Date:  2014-10-22       Impact factor: 3.869

6.  Sdhd ablation promotes thyroid tumorigenesis by inducing a stem-like phenotype.

Authors:  Amruta Ashtekar; Danielle Huk; Alexa Magner; Krista La Perle; Xiaoli Zhang; José I Piruat; José López-Barneo; Sissy M Jhiang; Lawrence S Kirschner
Journal:  Endocr Relat Cancer       Date:  2017-09-19       Impact factor: 5.678

7.  Familial Papillary Thyroid Carcinoma (FPTC): a Retrospective Analysis in a Sample of the Bulgarian Population for a 10-Year Period.

Authors:  Kalin Vidinov; Dragomira Nikolova
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

8.  Outcome of Treatment for Medullary Thyroid Carcinoma-a Single Centre Experience.

Authors:  Anish Jacob Cherian; Pooja Ramakant; Rekha Pai; Marie Therese Manipadam; S Elanthenral; Anuradha Chandramohan; Julie Hephzibah; David Mathew; Dhukabandhu Naik; Thomas V Paul; Simon Rajaratnam; Nihal Thomas; M J Paul; Deepak Thomas Abraham
Journal:  Indian J Surg Oncol       Date:  2017-12-08

Review 9.  The impact of family history on non-medullary thyroid cancer.

Authors:  I J Nixon; C Suárez; R Simo; A Sanabria; P Angelos; A Rinaldo; J P Rodrigo; L P Kowalski; D M Hartl; M L Hinni; J P Shah; A Ferlito
Journal:  Eur J Surg Oncol       Date:  2016-08-11       Impact factor: 4.424

Review 10.  Multifocal papillary thyroid carcinoma--a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Maurizio Iacobone; Svante Jansson; Marcin Barczyński; Peter Goretzki
Journal:  Langenbecks Arch Surg       Date:  2013-11-22       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.